课题基金 / 基金详情

Devlopment of MACIF as a new medicine for regulation of membrane attack complex of complement

Devlopment of MACIF as a new medicine for regulation of membrane attack complex of complement
MACIF作为调节补体膜攻击复合物的新药的开发
批准号:
02557103
负责人:
TOMITA Motowo
金额:
$8.96万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Developmental Scientific Research (B)
财政年份:
1990
资助国家:
日本
项目状态:
已结题
起止时间:
1990 至 1991

项目摘要

项目成果

TOMITA Motowo的其他基金

相似基金

相关文献

中文摘要
翻译
当这项研究在两年前开始时,我们关于Macif的证据有限。我们最初知道的Macif的性质是,Macif是一种糖基磷脂酰肌醇(GPL)锚定蛋白,能特异性地抑制同源互补的膜攻击复合体的形成。(1)利用现有的技术几乎不可能制备大量的膜形式的MACIF。(2)尝试用三种二聚体调味汁制备可溶形态的Macif,而不是膜形态的Macif。第一种来自人尿,含有约0.5 mg/L的可溶性形式。第二个和第三个分别来自大肠杆菌和CHO细胞,其中通过基因工程生产重组的可溶性形式的Macif。(3)Macif由77个氨基酸组成,一个N-糖苷寡糖单元和一个GPL-寡糖单元。尿液中含有两个单位,而来自大肠杆菌的重组形式没有单位,而来自CHO细胞的重组形式只有一个N-糖苷低聚糖单位。(4)用豚鼠红细胞和人补体的溶血抑制法测定,三种可溶性形式的活性仅为膜形式的0.1%。这一结果表明,MACIF的膜结合对活性是重要的,而碳水化合物部分对活性不是必需的。(5)尿Macif对恒河猴肾功能低下再灌流所致的细胞毒性有明显的保护作用,但其作用机制尚不清楚。
英文摘要
We had only a limited line of evidence on MACIF when this research had started two years ago. The properties of MACIF we knew at the beginning were that MACIF was a glycosylphosphatidylinositol(GPl)-anchored protein which specifically inhibited the formation of membrane attack complex of homologous complement.New findings obtained from this reseach project are as follows. (1) it was almost impossible to prepare a large amount of the membrane form of MACIFby using presently available techniques. (2) we tried to prepare the soluble forms of MACIF, instead of the membrane form by three dimerent sauces. The first one was from human urine which contained about 0.5 mg/L of the soluble form. The second and third ones were from Eschericia coli and CHO cells, respectively, in which recombinant soluble forms of MACIF were produced by gene engineering. (3) MACIF consists of 77 amino acids, a N-glycosidic oligosaccharide unit and a GPl-oligosaccharide unit. The urine form had both units, and the recombinant form from E. coli had no units while that from CHO cells had only a N-glycosidic oligosaccharide unit. (4) activities of the three soluble forms were only 0.1% as much as that of the membrane form wheer those activities were assayed by the inhibition of hemolysis using guinea pig erythrocytes and human complement. This result indicated that the membrane binding of MACIF was important for the activity, and the carbohydrate moieties were not essential for the activity. (5) the urine MACIF significantly protected the cytotoxicity caused by recirculation after kidney hypaemia of marmosets, although the reaction mechanism was not clear.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
Yuji Sugita, Yasuhiro Yamagishi, Takashi Tobe, Nam-Ho Miura, Yasuko Nakano and Motowo Tomita: "Isolation and characterization of soluble forms of MACIF (CD59 antigen) in human serum and urine" J. Immunol. Method.
Yuji Sugita、Yasuhiro Yamagishi、Takashi Tobe、Nam-Ho Miura、Yasuko Nakano 和 Motowo Tomita:“人血清和尿液中可溶形式 MACIF(CD59 抗原)的分离和表征”J.Immunol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nakano Yasuko: "Complete determination of disulfide bonds localized within the short consensus repeat inits of decay accelerating factor (CD55 antigen)" Biochim.Biophys.Acta.
Nakano Yasuko:“完整测定位于腐烂加速因子(CD55 抗原)的短一致重复序列内的二硫键”Biochim.Biophys.Acta。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Yasuko Nakano, Yuji Sugita, Yoko Ishikawa, Nam-Ho Choi, Takashi Tobe and Motowo Tomita: "Isolation of two forms of decay-accelerating factor (DAF) from human urine" Biochim. Biophys. Acta. 1074. 326-330 (1991)
Yasuko Nakano、Yuji Sugita、Yoko Ishikawa、Nam-Ho Choi、Takashi Tobe 和 Motowo Tomita:“从人尿中分离两种形式的腐烂加速因子 (DAF)”Biochim。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
NamーHo Choi: "Incorporation of SPー40,40 into the soluble membrane attack complex (SMAC,SCb5ー9) of complement" International Immunology. 2. 413-417 (1990)
Nam-Ho Choi:“将 SP-40,40 纳入补体的可溶性膜攻击复合物 (SMAC,SCb5-9)”《国际免疫学》2. 413-417 (1990)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 7 条
    An Adipocyte-specific Plasma Protein, Adiponectin/GBP28, functions as a mediator of biological defense mechanism.
    Characterization of physiological function of the plasma proteins, PFBP and IHRP with knockout mice.
    • 批准号:
      11470489
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.41万
    • 财政年份:
      1999
    • 负责人:
      TOMITA Motowo
    • 依托单位:
    Biological functions of novel human plasma proteins, IHRP and PHBP.
    • 批准号:
      08457615
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $5.06万
    • 财政年份:
      1996
    • 负责人:
      TOMITA Motowo
    • 依托单位:
    Search of a gene family containing MACIF, a regulatory membrane protein of complement system
    • 批准号:
      02454487
    • 项目类别:
      Grant-in-Aid for General Scientific Research (B)
    • 资助金额:
      $4.42万
    • 财政年份:
      1990
    • 负责人:
      TOMITA Motowo
    • 依托单位:
    国内基金
    海外基金
    补体抑制蛋白CD59调控海马抑制性突触传递在空间参考记忆中的作用及机制研究
    • 批准号:
      2025JJ60167
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2025
    • 负责人:
      文朗
    • 依托单位:
    M2 巨噬细胞通过外泌体调控 TRIM71 介导的 CD59 泛素化进而影响胶质瘤发生发展的机制研究
    • 批准号:
      2024JJ5561
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
      张明宇
    • 依托单位:
    脑出血后膜攻击复合物(MAC)协同CD59介导血肿内红细胞坏死性凋亡的机制研究
    • 批准号:
      --
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2022
    • 负责人:
      夏凡
    • 依托单位:
    pGalNAc-T4催化补体调节蛋白CD59上O-GalNAc糖基化修饰的发现及其生物学功能解析
    • 批准号:
      --
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      30万元
    • 批准年份:
      2022
    • 负责人:
      吴琼
    • 依托单位: